We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Climb Bio, Inc. (CLYM - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Climb Bio, Inc. is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Climb Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLYM's full-year earnings has moved 10.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, CLYM has gained about 143.3% so far this year. Meanwhile, stocks in the Medical group have gained about 2.9% on average. This shows that Climb Bio, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Halozyme Therapeutics (HALO - Free Report) . The stock has returned 82% year-to-date.
Over the past three months, Halozyme Therapeutics' consensus EPS estimate for the current year has increased 10.2%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Climb Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 449 individual stocks and currently sits at #98 in the Zacks Industry Rank. On average, this group has gained an average of 2.3% so far this year, meaning that CLYM is performing better in terms of year-to-date returns. Halozyme Therapeutics is also part of the same industry.
Climb Bio, Inc. and Halozyme Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Climb Bio, Inc. (CLYM - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Climb Bio, Inc. is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Climb Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLYM's full-year earnings has moved 10.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, CLYM has gained about 143.3% so far this year. Meanwhile, stocks in the Medical group have gained about 2.9% on average. This shows that Climb Bio, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Halozyme Therapeutics (HALO - Free Report) . The stock has returned 82% year-to-date.
Over the past three months, Halozyme Therapeutics' consensus EPS estimate for the current year has increased 10.2%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Climb Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 449 individual stocks and currently sits at #98 in the Zacks Industry Rank. On average, this group has gained an average of 2.3% so far this year, meaning that CLYM is performing better in terms of year-to-date returns. Halozyme Therapeutics is also part of the same industry.
Climb Bio, Inc. and Halozyme Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.